Novo Nordisk reports nearly 28% weight loss in early responders to higher-dose Wegovy

Novo Nordisk presented analyses on May 12, 2026 showing that higher-dose Wegovy (semaglutide 7.2 mg) produced nearly 28% weight loss in participants who responded early in the STEP UP program, according to data shared at the European Congress on Obesity ^[1].

The 7.2 mg dose is sold as Wegovy HD. The FDA approved it on March 19, 2026, in an announcement that described it as delivering the highest weight loss to date for a Wegovy injection ^[1]. Wegovy HD comes in a prefilled, single-dose pen. The Wegovy injection line includes pens that deliver 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg and the 7.2 mg HD dose ^[1].

The nearly 28% figure applies to a subgroup — people who responded early during treatment — and not to everyone who took the drug. In June 2025, Novo Nordisk reported that a higher dose of Wegovy produced average weight loss of 21% in people with obesity, with about a third of participants losing 25% or more ^[1]. The difference between 21% and nearly 28% reflects the gap between a whole-study average and a selected group that lost weight quickly.

The same conference included other analyses. A separate report dated May 13, 2026 said the Wegovy pill, oral semaglutide 25 mg, delivered 21.6% weight loss in early responders ^[1]. Another analysis presented May 12, 2026 covered weight loss in women across menopause stages, along with heart and migraine findings ^[1].

Wegovy was first approved by the FDA on June 4, 2021, for adults with obesity ^[1]. It now also carries approvals to reduce the risk of major cardiovascular events in adults with established cardiovascular disease and either obesity or overweight, granted March 2024, and an accelerated approval to treat noncirrhotic MASH with moderate to advanced liver fibrosis, granted August 2025 ^[1]. The label carries a boxed warning for an increased risk of thyroid C-cell tumors, and lists nausea, diarrhea, vomiting, constipation and abdominal pain among the most common side effects ^[1].

Several details of the STEP UP early-responder analysis have not been reported: how many participants were counted as early responders, how early response was defined, and what the average weight loss was across all participants taking 7.2 mg. It also has not been reported whether the analysis has been published in a peer-reviewed journal.

Why it matters for patients

A number like nearly 28% can set expectations high, but it describes a subset of people who were already losing weight quickly. The average result reported earlier for higher-dose Wegovy was about 21%, and roughly a third of participants in that analysis lost 25% or more ^[1]. Two people taking the same dose can have very different results, and the early-responder figures do not predict what any one person will experience.

Wegovy HD is not a future product — it is already approved and supplied in pens that deliver 7.2 mg ^[1]. Cost has also been shifting. Novo Nordisk cut U.S. list prices for Wegovy, Ozempic and Rybelsus on February 24, 2026 ^[1], launched NovoCare Pharmacy in March 2025 at $499 per month for all approved Wegovy doses ^[1], and started a multi-month subscription program on March 31, 2026 that the company said could save up to $1,200 a year ^[1]. Coverage and out-of-pocket costs still depend on a person's insurance plan, and those details have not been disclosed in these announcements.

Semaglutide products should not be combined with other semaglutide-containing medicines or other GLP-1 receptor agonists, according to the label ^[1].

What happens next

No timeline for peer-reviewed publication of the STEP UP early-responder analysis, or for any regulatory filing based on it, has been reported. Novo Nordisk presented multiple semaglutide analyses at the European Congress on Obesity on May 12 and 13, 2026 ^[1]; fuller trial results, including the size of the early-responder group, have not been disclosed.